tirzepatide cardiovascular outcomes 💉 In a large real-world study, was associated with a lower incidence of major vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart tirzepatide cardiovascular outcomes and Outcomes:

King A, Tan X, Dhopeshwarkar N, Bohn R, Dea K, Leonard CE et al

Tirzepatide (Zepbound) : a dual GIP/GLP-1 receptor agonist, also once weekly, that may help support weight care and metabolic health

5355 However, data are scarce regarding the relationship between GST and clinical response to chemotherapy

and papers cited therein)

Available from Accessed 1 Mar 2023 Ethics declarations Data availability To gain access to the data in the TriNetX research network, a request can be made to TriNetX ( but costs may be incurred, a data sharing agreement would be necessary and no patient identifiable information can be obtained